Edwin Rock
Technik-/Wissenschafts-/F&E-Leiter bei GLYCOMIMETICS, INC.
Vermögen: 184 389 $ am 31.05.2024
Profil
Edwin P.
Rock is currently the Chief Medical Officer & Senior Vice President at GlycoMimetics, Inc. Prior to his current position, he served as the Chief Medical Officer at Partner Therapeutics, Inc. Dr. Rock completed his undergraduate degree at Swarthmore College and obtained his doctorate from Stanford University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
1,06% | 21.06.2024 | 680 403 ( 1,06% ) | 184 389 $ | 31.05.2024 |
Aktive Positionen von Edwin Rock
| Unternehmen | Position | Beginn |
|---|---|---|
| GLYCOMIMETICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 06.09.2022 |
Ehemalige bekannte Positionen von Edwin Rock
| Unternehmen | Position | Ende |
|---|---|---|
Partner Therapeutics, Inc.
 Partner Therapeutics, Inc. BiotechnologyHealth Technology Partner Therapeutics, Inc. develops and commercializes therapeutics that improves health and economic outcomes in the treatment of cancer. Its development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company is headquartered in Boston, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Edwin Rock
| Swarthmore College | Undergraduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Partner Therapeutics, Inc.
Partner Therapeutics, Inc. BiotechnologyHealth Technology Partner Therapeutics, Inc. develops and commercializes therapeutics that improves health and economic outcomes in the treatment of cancer. Its development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company is headquartered in Boston, MA. | Health Technology |
